Nurix Therapeutics, Inc. (NRIX) Stock
NRIX has an Alpha Score of 80 out of 100 (strong), computed on Oct 25, 2026 from 3 of 4 sub-scores. 5 of the hedge funds AlphaScala tracks reported NRIX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is ARK Invest's at $43.50M. Company insiders reported 0 open-market buys and 15 sales on SEC Form 4 in the 90 days to Oct 23, 2026. Its trailing P/E ratio is 9.7 and its net margin 42.0% (key statistics as of Oct 21, 2026).
What is NRIX's Alpha Score?
How it works →Alpha Score of 79 reflects strong overall profile with strong momentum, strong value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 25, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own NRIX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| ARK Invest Cathie Wood | 1.79M | $43.50M | +4% |
| Citadel Ken Griffin | 1.48M | $35.83M | +10% |
| D.E. Shaw David Shaw | 185K | $4.48M | -46% |
| Point72 Steve Cohen | 73K | $1.77M | -84% |
| Millennium Management Israel Englander | 21K | $507.3K | -96% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Nurix Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 15, 26 | Hansen Gwenn | Chief Scientific Officer | SELL | 1.5K | $36K |
| Oct 14, 26 | Gregory Julia P | Director | SELL | 22.6K | $529K |
| Oct 2, 26 | Ring Christine | Chief Legal Officer | SELL | 5.8K | $134K |
| Sep 2, 26 | Ring Christine | Chief Legal Officer | SELL | 5.4K | $138K |
| Sep 2, 26 | Ring Christine | Chief Legal Officer | SELL | 400 | $11K |
| Sep 1, 26 | Hansen Gwenn | Chief Scientific Officer | SELL | 1.5K | $37K |
| Aug 5, 26 | Hansen Gwenn | Chief Scientific Officer | SELL | 4.4K | $109K |
| Aug 4, 26 | Van Houte Hans | Chief Financial Officer | SELL | 1.8K | $43K |
| Aug 4, 26 | Van Houte Hans | Chief Financial Officer | SELL | 3.0K | $73K |
| Aug 4, 26 | Hansen Gwenn | Chief Scientific Officer | SELL | 1.5K | $36K |
SEC Form 4 filings as of Oct 23, 2026
See cluster-buy signals across all tickers →What are NRIX's key statistics?
Key statistics as of Oct 21, 2026
How does NRIX's valuation compare with the Healthcare sector?
| Metric | NRIX | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 9.7 | 26.9 | 83 |
| Net margin | 42.01% | 8.32% | 109 |
| Return on equity | 49.34% | 10.56% | 118 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Oct 26, 2026). P/E excludes loss-making companies.
NRIX price chart
Powered by TradingViewWhat does Nurix Therapeutics, Inc. do?
Nurix Therapeutics Inc. is a biotechnology firm focused on developing therapies to address immune system disorders and cancers. At the heart of its innovative approach is the modulation of protein levels within cells, a critical factor in disease progression. Nurix employs its proprietary DELigase platform to discover and design targeted therapies that either enhance or degrade specific proteins through ubiquitin proteasome system engagement. By manipulating the protein degradation pathways, the company aims to offer new treatment paradigms where traditional therapeutics may fall short. Nurix Therapeutics' research and product pipeline significantly influences the biotechnology and pharmaceutical sectors, with emphasis on immuno-oncology, a rapidly growing field within cancer treatment. Formed through scientific expertise and collaborations, the company encapsulates significant market insights by translating breakthroughs in protein homeostasis into potential life-altering therapies, thus playing a pivotal role in advancing personalized medicine.